New Treatment Options for Relapsed/Recurrent DLBCL: Impact on Sequencing Therapeutic Choices - Episode 16

Disparities in access to newer or expensive treatments, unmet needs in the treatment of DLBCL

, , ,

A panel of experts discuss the current treatment landscape for bispecific antibodies and CAR T in R/R DLBCL.

Video content above is prompted by the following:

  • What are your thoughts on the current treatment landscape for bispecific antibodies and CAR T in R/R DLBCL, specifically related to sequencing and transplant eligibility?